Evidence map›Paper›PMID 37724607›Full record

ArticleCancer medicine2023

Real-world experience of tyrosine kinase inhibitors in children, adolescents and adults with relapsed or refractory bone tumours: A Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) study.

Hagit Peretz Soroka, Tushar Vora, Jonathan Noujaim, Nicolas Marcoux, Sarah Cohen-Gogo, Thierry Alcindor, Caroline Holloway, Caroline Rodrigues, Hatim Karachiwala, Saima Alvi and 9 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Targeted and molecular therapies in Ewing sarcoma: a comprehensive review of preclinical and clinical advances.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 10 institutions in 1 country.

Hagit Peretz SorokaDivision of Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
Tushar VoraDivision of Hematology/Oncology, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
Jonathan NoujaimDivision of Medical Oncology, Hôpital Maisonneuve Rosemont, University of Montreal, Montreal, Quebec, Canada.
Nicolas MarcouxDivision of Hematology-Oncology, Centre Hospitalier Universitaire de Québec, Quebec, Canada.
Sarah Cohen-GogoDivision of Hematology/Oncology, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
Thierry AlcindorDivision of Medical Oncology, McGill University Health Centre, Montreal, Quebec, Canada.
Caroline HollowayDivision of Radiation Oncology, BC Cancer, University of British Columbia, Vancouver, British Columbia, Canada.
Caroline RodriguesDivision of Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
Hatim KarachiwalaDivision of Medical Oncology, Cross Cancer Institute, Alberta Health Services, Edmonton, Alberta, Canada.
Saima AlviDivision of Pediatric Hematology/Oncology, Jim Pattison Children's Hospital Saskatoon, Saskatoon, Saskatchewan, Canada.
Ursula LeeDivision of Medical Oncology, BC Cancer, University of British Columbia, Vancouver, British Columbia, Canada.
Sylvia ChengDivision of Pediatric Hematology/Oncology/BMT, B.C. Children's Hospital, BC Cancer, Vancouver, British Columbia, Canada.
Shantanu BanerjiDepartment of Pediatric Hematology-Oncology, CancerCare Manitoba Research Institute, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
Sapna OberoiDepartment of Pediatric Hematology-Oncology, CancerCare Manitoba Research Institute, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.ORCID 0000-0002-6071-0042
Xiaolan FengDivision of Medical Oncology, BC Cancer, University of British Columbia, Vancouver, British Columbia, Canada.
Alannah SmrkeDivision of Medical Oncology, BC Cancer, University of British Columbia, Vancouver, British Columbia, Canada.
Christine SimmonsDivision of Medical Oncology, BC Cancer, University of British Columbia, Vancouver, British Columbia, Canada.
Albiruni Abdul RazakDivision of Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
Abha A GuptaDivision of Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.ORCID 0000-0002-0825-5070
BC Cancer Agency · CAUniversity of Toronto · CACancerCare Manitoba · CAAlberta Health Services · CABC Children's Hospital · CACentre hospitalier universitaire de Québec · CAHôpital Maisonneuve-Rosemont · CAMcGill University Health Centre · CAMount Sinai Hospital · CASaskatoon City Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesWe conducted a retrospective multi-centre study to assess the real-world outcome of regorafenib (REGO) and cabozantinib (CABO) in recurrent/refractory bone tumours (BTs) including osteosarcoma (OST), Ewing sarcoma (EWS) and chondrosarcoma (CS)/extra-skeletal mesenchymal CS (ESMC).

methodsAfter regulatory approval, data from patients with recurrent BT (11 institutions) were extracted from CanSaRCC (Canadian Sarcoma Research and Clinical Collaboration) database. Patient characteristics, treatment and outcomes were collected. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method.

resultsFrom July 2018 to May 2022, 66 patients received REGO or CABO; 39 OST, 18 EWS, 4 CS and 5 ESMC. Median age was 27.8 years (range 12-76); median starting dose was 60 mg for CABO (n = 37, range 40-60) and 120 mg for REGO (n = 29, range 40-160). Twenty-eight (42.4%) patients required dose reduction: hand-foot syndrome 7 (10.6%), nausea/vomiting 1 (1.5%), diarrhoea 1 (1.5%), 2 elevated LFTs (3%), elevated bilirubin 1 (1.5%) and mucositis 1 (1.5%). The median OS for patients with OST, EWS, CS and ESMC was 8.5 months (n = 39, 95% CI 7-13.1); 13.4 months (n = 18, 95% CI 3.4-27.2), 8.1 (n = 4, 95% CI 4.1-9.3) and 18.2 (n = 5, 95% CI (10.4-na), respectively. Median PFS for OST, EWS, CS and ECMS was 3.5 (n = 39, 95% CI 2.8-5), 3.9 (n = 18, 95% CI 2.1-5.9), 5.53 (n = 4. 95% CI 2.13-NA) and 11.4 (n = 5, 95% CI 1.83-14.7), respectively. Age, line of therapy, REGO versus CABO, or time from diagnosis to initiation of TKI were not associated with PFS on univariable analysis.

conclusionOur real-world data show that TKIs have meaningful activity in recurrent BT with acceptable toxicities when started at modified dosing. Inclusion of TKIs in earlier lines of treatment and/or maintenance therapy could be questions for future research.

Indexed as

Bone NeoplasmsChondrosarcomaOsteosarcomaSarcomaSarcoma, EwingSoft Tissue NeoplasmsAdolescentAdultAgedCanadaChildHumansMiddle AgedNeoplasm Recurrence, LocalPhenylurea CompoundsPyridinesPhenylurea CompoundsPyridinesregorafenibTyrosine Kinase InhibitorscabozantanibCanSaRCCchondrosarcomaEwing sarcomaosteosarcomaregorafenib

Identifiers

PMID37724607
PMCPMC10557866
OpenAlexW4386845937

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.